Compare Stocks → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ASTCNASDAQ:PRPONASDAQ:SQLNASDAQ:TLIS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASTCAstrotech$9.38+1.2%$8.59$7.00▼$15.11$15.94M-0.173,330 shs698 shsPRPOPrecipio$6.15-2.8%$6.41$4.75▼$14.80$8.79M1.616,248 shs3,618 shsSQLSeqLL$4.16$6.50▼$96.00$2.52M1.3452,119 shs22,000 shsTLISTalis Biomedical$9.05+0.6%$8.57$4.35▼$9.32$16.47M1.748,708 shs8,438 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASTCAstrotech+0.55%-6.44%+5.33%+28.51%-16.05%PRPOPrecipio+2.10%-6.02%+5.15%-3.21%-51.69%SQLSeqLL0.00%0.00%+106.25%+71.32%-60.98%TLISTalis Biomedical+1.12%+6.01%-1.10%+15.98%+18.18%Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASTCAstrotech0.7861 of 5 stars0.04.00.00.01.92.50.6PRPOPrecipio0.3379 of 5 stars2.03.00.00.00.00.80.6SQLSeqLLN/AN/AN/AN/AN/AN/AN/AN/ATLISTalis Biomedical0.2435 of 5 stars0.54.00.00.00.02.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASTCAstrotechN/AN/AN/AN/APRPOPrecipioN/AN/A$40.00550.41% UpsideSQLSeqLLN/AN/AN/AN/ATLISTalis Biomedical1.00Sell$5.00-44.75% DownsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASTCAstrotech$750K21.25N/AN/A$26.55 per share0.35PRPOPrecipio$15.20M0.58N/AN/A$10.16 per share0.61SQLSeqLL$80K0.00N/AN/A$14.70 per share0.00TLISTalis Biomedical$2.13M7.73N/AN/A$37.95 per share0.24Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASTCAstrotech-$9.64M-$6.30N/A∞N/A-515.23%-23.57%-22.21%5/9/2024 (Estimated)PRPOPrecipio-$5.85M-$4.56N/A∞N/A-38.51%-51.75%-37.93%5/10/2024 (Estimated)SQLSeqLL-$4.09M-$16.40N/AN/AN/AN/A-124.09%-64.18%N/ATLISTalis Biomedical-$62.01M-$34.18N/A∞N/A-2,905.67%-69.49%-54.15%5/9/2024 (Estimated)Latest ASTC, TLIS, PRPO, and SQL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023TLISTalis BiomedicalN/A-$7.39-$7.39-$7.39N/A$0.20 million2/12/2024Q2 2024ASTCAstrotechN/A-$1.62-$1.62-$1.62N/A$1.12 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASTCAstrotechN/AN/AN/AN/AN/APRPOPrecipioN/AN/AN/AN/AN/ASQLSeqLLN/AN/AN/AN/AN/ATLISTalis BiomedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASTCAstrotechN/A17.3116.42PRPOPrecipio0.011.171.05SQLSeqLL0.505.045.04TLISTalis BiomedicalN/A8.868.86OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASTCAstrotech24.35%PRPOPrecipio10.45%SQLSeqLL1.82%TLISTalis Biomedical43.77%Insider OwnershipCompanyInsider OwnershipASTCAstrotech11.50%PRPOPrecipio10.60%SQLSeqLL22.30%TLISTalis Biomedical46.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASTCAstrotech221.70 million1.51 millionNot OptionablePRPOPrecipio511.43 million1.28 millionNo DataSQLSeqLL7381,000296,000Not OptionableTLISTalis Biomedical991.82 million984,000No DataASTC, TLIS, PRPO, and SQL HeadlinesSourceHeadlineTalis Biomedical Corporation (TLIS)finance.yahoo.com - March 31 at 8:16 AMGrabar Law Office Investigates Claims on Behalf of Shareholders of Talis Biomedical Corporationmarkets.businessinsider.com - February 16 at 8:42 PMTLIS Feb 2024 2.500 putfinance.yahoo.com - February 15 at 2:52 AMPeninsula diagnostics company to close Redwood City labs and offices, pursue 'strategic alternatives'bizjournals.com - November 14 at 8:38 PMTalis Biomedical Corporation: Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cashfinanznachrichten.de - November 14 at 3:36 PMLICY, BTAI and HROW among mid-day moversmsn.com - November 14 at 3:36 PMTalis reviewing strategic alternatives, stock rallies 35%msn.com - November 14 at 3:36 PMWhy Talis Biomedical (TLIS) Stock Is Exploding Highermsn.com - November 14 at 3:36 PMTalis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cashfinance.yahoo.com - November 14 at 3:36 PMBiomedical Engineering (BME) and Biomedical Science (BMS) Programsdrexel.edu - October 23 at 1:39 AMBTIG Maintains Talis Biomedical (TLIS) Sell Recommendationmsn.com - August 16 at 3:29 PMBTIG Maintains Sell Rating for Talis Biomedical: Here's What You Need To Knowmarkets.businessinsider.com - August 16 at 3:29 PMTalis Biomedical Announces Second Quarter 2023 Financial Results and Business Updatefinance.yahoo.com - August 11 at 12:45 AMA Preview Of Talis Biomedical's Earningsbenzinga.com - August 9 at 2:02 PMTalis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023finance.yahoo.com - August 3 at 12:25 PMTalis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)finance.yahoo.com - August 2 at 12:20 PMTLIS - Talis Biomedical Corporationuk.finance.yahoo.com - August 1 at 4:18 PMTalis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirementfinance.yahoo.com - July 24 at 10:12 AMTalis Biomedical Announces 1-for-15 Reverse Stock Splitfinance.yahoo.com - July 5 at 9:12 AMTalis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Directorfinance.yahoo.com - May 23 at 1:12 PMTalis Biomedical Corporation: Talis Biomedical Announces Business Update and First Quarter 2023 Financial Resultsfinanznachrichten.de - May 12 at 8:33 AMTalis Biomedical reports Q1 resultsseekingalpha.com - May 11 at 8:53 PMTalis Biomedical: Q1 Earnings Insightsmsn.com - May 11 at 8:53 PMTalis Biomedical Corporation (TLIS) Investor News: Robbins LLP Reminds Investors it is Investigating TLIS on Behalf of Shareholdersbenzinga.com - May 9 at 1:50 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAstrotechNASDAQ:ASTCAstrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology. The company also develops TRACER 1000, a mass spectrometer-based explosive trace detector to replace the explosives trace detectors used at airports, cargo and other secured facilities, and borders. In addition, it develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. Further, the company develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. The company was incorporated in 1984 and is based in Austin, Texas.PrecipioNASDAQ:PRPOPrecipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.SeqLLNASDAQ:SQLSeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.Talis BiomedicalNASDAQ:TLISTalis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.